pertuzumab   Click here for help

GtoPdb Ligand ID: 5046

Synonyms: 2C4 | Omnitarg® (obsolete trade name) | Perjeta®
Approved drug
pertuzumab is an approved drug (FDA (2012), EMA (2013))
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available in its IMGT/mAB-DB record.
Click here for help
1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Cancer Immunol Immunother, 55 (6): 717-27. [PMID:16151804]
2. Badache A, Hynes NE. (2004)
A new therapeutic antibody masks ErbB2 to its partners.
Cancer Cell, 5 (4): 299-301. [PMID:15093533]
3. Ferguson KM. (2004)
Active and inactive conformations of the epidermal growth factor receptor.
Biochem Soc Trans, 32 (Pt 5): 742-5. [PMID:15494003]
4. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G et al.. (2013)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.
Breast Care (Basel), 8 (1): 49-55. [PMID:24715843]
5. Kao Y-H, Vanderlaan M. (2006)
Her2 antibody composition.
Patent number: WO2006033700. Assignee: Genentech Inc.. Priority date: 22/07/2004. Publication date: 30/04/2010.